started · updated
Neuralink prepares Blindsight vision-restoration trials
Neuralink is preparing for its first Blindsight human trials, a brain-computer interface designed to restore visual perception by stimulating the visual cortex directly. The technology aims to assist individuals who are not candidates for retinal or optic-nerve solutions.
Elon Musk has indicated that the company intends to perform its first vision implants within six to 12 months, contingent upon regulatory approval. While the initial visual resolution is expected to be low—described by Musk as being akin to “Atari graphics”—the long-term goal is to improve resolution over time.
The Blindsight program received Breakthrough Device Designation from the FDA in September 2024, which provides prioritized review but does not guarantee safety or effectiveness. While Neuralink’s clinical trials page currently lists active studies for speech decoding, robotic-arm control, and computer control, the Blindsight study is officially categorized as an upcoming trial. Preclinical milestones include successful testing in animals, such as a domestic cat and monkeys.